```html

Uveoretinal Mosaicism: A Complete Patient‑Friendly Guide

Overview

Uveoretinal mosaicism is a rare ocular condition in which patches of abnormal retinal pigment or vascular tissue coexist with normal retinal tissue, creating a “mosaic” pattern visible on ophthalmic imaging. The abnormal patches can involve the retina, the uveal tract (iris, ciliary body, choroid), or both, leading to visual disturbances that vary from mild to severe.

Because the condition is uncommon, precise prevalence data are limited. Current case‑series and registry reports suggest an incidence of roughly 1–3 per 100,000 individuals, with a slight male predominance (≈55 %). Most patients are diagnosed in the second to fourth decade of life, though a few congenital forms have been reported.

Uveoretinal mosaicism can be isolated (idiopathic) or associated with systemic syndromes such as Neurofibromatosis type 1, Sturge‑Weber syndrome, or certain genetic pigmentary disorders (e.g., ocular albinism). Understanding the nature of the disease helps patients and clinicians monitor for associated systemic findings.

Symptoms

Symptoms depend on the size, location, and activity of the mosaic lesions. Below is a complete list of the most frequently reported complaints, along with a brief description of each.

• Blurred or reduced central vision – When lesions involve the macula, patients notice difficulty reading or recognizing faces.
• Peripheral visual field loss – Lesions in the peripheral retina may create scotomas (dark spots) or a “tunnel‑vision” effect.
• Photophobia – Increased light sensitivity, especially in bright environments.
• Glare and halos – Light sources may appear surrounded by bright rings.
• Floaters – Small, moving specks caused by vitreous traction over irregular retinal surfaces.
• Color distortion (metamorphopsia) – Straight lines may appear wavy, particularly when macular involvement is present.
• Eye pain or discomfort – Usually mild and related to concurrent uveitis (inflammatory component).
• Redness or tearing – May accompany episodic inflammatory flares.
• Flashing lights (photopsia) – Sudden bursts of light can herald retinal traction or impending detachment.
• Decreased night vision – Difficulty seeing in low‑light situations, especially if the choroid is involved.

Not all patients experience every symptom; many are asymptomatic and discovered incidentally during routine eye examinations.

Causes and Risk Factors

Primary (Idiopathic) Mosaicism

In most cases, the exact cause remains unknown. Researchers believe a combination of developmental errors during embryonic eye formation and post‑natal retinal remodeling contributes to the patchy appearance.

Genetic and Syndromic Associations

• Neurofibromatosis type 1 (NF1) – Mutations in the NF1 gene can cause choroidal abnormalities that appear as a mosaic pattern.
• Sturge‑Weber syndrome – Vascular malformations affecting the leptomeninges and choroid may produce a similar retinal mosaic.
• Ocular albinism & other pigmentary disorders – Abnormal melanin synthesis leads to irregular pigment distribution.
• Genetic mosaicism – Somatic mutations occurring after fertilization can create patches of cells with distinct genetic makeup, manifesting as retinal mosaicism.

Acquired Risk Factors

• Inflammatory eye disease – Chronic uveitis can induce localized atrophy or hyperpigmentation that mimics mosaicism.
• Trauma or ocular surgery – Scarring and pigment dispersion after injury or procedures (e.g., retinal detachment repair) may generate mosaic‑like changes.
• Systemic autoimmune disorders – Conditions such as sarcoidosis can involve the uvea and create patchy lesions.

Diagnosis

Diagnosing uveoretinal mosaicism requires a thorough ophthalmic exam combined with modern imaging technologies. The goal is to confirm the characteristic mosaic pattern, assess lesion activity, and rule out mimicking conditions (e.g., choroidal nevi, inflammatory scars).

Clinical Examination

• Visual acuity testing – Baseline measurement of central vision.
• Dilated fundus examination – Direct ophthalmoscopy or slit‑lamp biomicroscopy to visualize retinal and choroidal patches.
• Intra‑ocular pressure (IOP) measurement – Important if secondary glaucoma is suspected.

Imaging Modalities

• Fundus photography – High‑resolution color images document the mosaic pattern and track changes over time.
• Optical Coherence Tomography (OCT) – Provides cross‑sectional views of retinal layers; hyper‑reflective or hyporeflective zones correspond to mosaic patches.
• Fundus Autofluorescence (FAF) – Highlights abnormal lipofuscin accumulation in the retinal pigment epithelium.
• Fluorescein Angiography (FA) & Indocyanine Green Angiography (ICGA) – Evaluate retinal and choroidal blood flow; mosaic lesions often show irregular filling patterns.
• Ultrasound B‑scan – Useful when media opacities (e.g., cataract) limit view of the posterior segment.

Laboratory Tests (when a systemic association is suspected)

• Complete blood count, ACE level, and lysozyme – Screen for sarcoidosis.
• Genetic testing for NF1 or other relevant mutations if a syndromic link is suspected.

Differential Diagnosis

Conditions that can resemble uveoretinal mosaicism include choroidal nevi, retinal pigment epithelium (RPE) hyperplasia, serpiginous choroiditis, and early age‑related macular degeneration. A comprehensive work‑up helps avoid misdiagnosis.

Treatment Options

Treatment is individualized based on lesion activity, visual impact, and any underlying systemic disease. The main goals are to preserve vision, control inflammation, and prevent complications.

Observation

Many patients with stable, non‑progressive lesions require only regular monitoring (every 6–12 months). Lifestyle counseling and protection from ultraviolet (UV) light are recommended.

Pharmacologic Therapy

• Corticosteroid eye drops (e.g., prednisolone acetate 1%) – For mild anterior uveitis associated with mosaic lesions.
• Periocular or intravitreal steroids (triamcinolone, dexamethasone implant) – Used when inflammation threatens the macula or retina.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) – Oral or topical NSAIDs can help control low‑grade inflammation.
• Immunomodulatory agents (e.g., methotrexate, mycophenolate mofetil) – Considered for chronic, steroid‑dependent uveitis.
• Anti‑VEGF injections – If secondary choroidal neovascularization (CNV) develops, agents like ranibizumab or aflibercept are effective.

Surgical Interventions

• Laser photocoagulation – Targets focal CNV or leaking choroidal lesions.
• Pneumatic retinopexy or scleral buckle – Indicated if a retinal detachment arises from traction on mosaic areas.
• Pars plana vitrectomy – Used for vitreous hemorrhage or tractional membranes associated with the mosaic tissue.

Lifestyle & Supportive Measures

• Wear broad‑spectrum sunglasses (UV‑A/B) to reduce phototoxic stress on the retina.
• Use a low‑glare reading lamp and avoid prolonged screen exposure without breaks (20‑20‑20 rule).
• Control systemic risk factors (e.g., hypertension, diabetes) that can aggravate retinal vascular health.

Living with Uveoretinal Mosaicism

Adapting to a chronic eye condition involves practical strategies that protect vision and improve quality of life.

• Regular eye‑care appointments – At least annually, or more often if vision changes.
• Vision rehabilitation – Low‑vision aids (magnifiers, high‑contrast reading glasses) can help when central vision is compromised.
• Protective eyewear – In addition to sunglasses, wear safety goggles during sports or hazardous activities.
• Medication adherence – Set reminders for drops or oral meds; missing doses can precipitate inflammatory flares.
• Monitor for systemic signs – If you have a known associated syndrome, stay vigilant for new skin lesions, neurological symptoms, or headaches.
• Psychosocial support – Joining patient support groups (e.g., Uveitis Foundation) can reduce anxiety and provide practical tips.

Prevention

Because many cases are idiopathic or genetically determined, primary prevention is limited. However, you can reduce the risk of secondary worsening:

• Control systemic diseases (hypertension, diabetes, autoimmune disorders).
• Avoid smoking – It accelerates retinal vascular damage.
• Use UV‑blocking sunglasses daily.
• Promptly treat ocular infections or inflammation to prevent scar formation.
• Follow safe practices during eye surgery or trauma (protective eyewear).

Complications

If left untreated or poorly managed, uveoretinal mosaicism can lead to several serious outcomes:

• Choroidal neovascularization (CNV) – New, abnormal blood vessels that leak fluid or bleed, causing rapid vision loss.
• Retinal detachment – Traction from irregular tissue may separate the retina from the underlying pigment epithelium.
• Secondary glaucoma – Chronic inflammation or steroid use can raise intra‑ocular pressure.
• Cataract formation – Prolonged steroid therapy increases cataract risk.
• Permanent central or peripheral vision loss – Resulting from scar tissue or atrophy.
• Systemic manifestations – In syndromic cases, untreated disease may signal progression of neurofibromatosis, Sturge‑Weber or other systemic complications.

When to Seek Emergency Care

References

1. Mayo Clinic. Uveitis. https://www.mayoclinic.org/diseases-conditions/uveitis (accessed June 2026).

2. National Eye Institute (NEI). Facts About Retinal Disorders. https://www.nei.nih.gov.

3. NCCN Clinical Practice Guidelines in Oncology: Neurofibromatosis Type 1. 2023.

4. Patel, S. et al. “Mosaic Retinal Pigmentary Alterations in Sturge‑Weber Syndrome.” Ophthalmology Retina, 2022.

5. World Health Organization. Global Data on Vision Impairment. 2021.

```